Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study

被引：0
|
作者：
Cliff Molife
Katherine B. Winfree
Hollie Bailey
Yulia D’yachkova
Cameron Forshaw
Sangmi Kim
Kaisa-Leena Taipale
Tarun Puri
机构：
[1] Eli Lilly and Company,Value, Evidence, and Outcomes
[2] Lilly Corporate Center,Oncology
[3] Adelphi Real World,Lilly International Medical Affairs Oncology
[4] Statistics,undefined
[5] Eli Lilly and Company,undefined
[6] Global Patient Safety-Pharmacoepidemiology,undefined
[7] Eli Lilly and Company,undefined
[8] Value,undefined
[9] Evidence,undefined
[10] and Outcomes-International,undefined
[11] Eli Lilly and Company,undefined
[12] Eli Lilly and Company,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Advanced non-small cell lung cancer; Disease Specific Programme™; mutation; Patient-reported outcomes; Point-in-time; Real-world; Survey; Treatment patterns;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3135 / 3168
页数：33
相关论文
共 50 条
  • [41] How to Treat EGFR-Mutated Non-Small Cell Lung Cancer
    Belani, Neel
    Liang, Katherine
    Fradley, Michael
    Judd, Julia
    Borghaei, Hossein
    JACC: CARDIOONCOLOGY, 2023, 5 (04): : 542 - 545
  • [42] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [43] Real-World Biomarker Testing and Treatment Patterns for Locally Advanced and Metastatic Non-Small Cell Lung Cancer in Canada
    Laforty, C.
    Tong, M.
    Sharma, A.
    Kim, Y.
    Devost, N.
    Qadeer, R.
    Navani, V.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S656 - S657
  • [44] Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America
    Martin, Claudio
    Cuello, Mauricio
    Barajas, Olga
    Recondo, Gonzalo
    Aruachan, Sandra
    Perroud, Herman
    Sena, Susana
    Bonilla, Carlos
    Orlandi, Francisco
    Beruttii, Susana
    Cocco, Virginia Garcia
    Gomez, Alvaro
    Korbenfeld, Ernesto
    Zapata, Maycos
    Cundom, Juan
    Orellana, Eric
    Goncalves, Susana
    Reinhold, Florencia
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (01)
  • [45] Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
    Rao, Ding-Yu
    Huang, De-Fa
    Si, Mao-Yan
    Lu, Hua
    Tang, Zhi-Xian
    Zhang, Zu-Xiong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy
    Patel, Jyoti
    Meng, Jie
    Le, Hoa
    Tanaka, Yoko
    Phani, Sudarshan
    Salas, Maribel
    Wu, Chuntao
    Sternberg, David
    Esker, Stephen
    Anderson, Jeffrey P.
    Crowley, Aaron
    Zhou, Summera Q.
    Lieb, Camryn
    Sun, Haiyan
    Doan, Quan V.
    Santhanagopal, Anu
    Reckamp, Karen L.
    ADVANCES IN THERAPY, 2024, 41 (08) : 3299 - 3315
  • [47] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    EXPERT OPINION ON PHARMACOTHERAPY, 2025,
  • [48] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [49] A real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib.
    Viray, Hollis
    Piper-Vallillo, Andrew
    Widick, Page
    Academia, Emmeline
    Shea, Meghan
    Rangachari, Deepa
    Costa, Daniel Botelho
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer
    Bazhenova, Lyudmila
    Kish, Jonathan
    Cai, Beilei
    Caro, Nydia
    Feinberg, Bruce
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 33
12345